MZ
Therapeutic Areas
IO Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IO102-IO103 (Cylembio®) + pembrolizumab | First-line Advanced Melanoma | Phase 3 |
| IO102-IO103 + pembrolizumab | Adjuvant Treatment of Melanoma | Phase 2 |
| IO102-IO103 + nivolumab | Advanced Solid Tumors (e.g., NSCLC, Bladder Cancer) | Phase 1/2 |
Leadership Team at IO Biotech
QA
Qasim Ahmad
Chief Medical Officer
AS
Amy Sullivan
Chief Financial Officer
DS
Devin Smith
General Counsel
EF
Eric Faulkner
Chief Technical Officer
FM
Faiçal Miyara
Chief Business Officer
DG
Daniel G. Mannix
Senior Vice President, Regulatory Affairs
MH
Mads Hald Andersen
Co-Founder, Scientific Advisor
IM
Inge Marie Svane
Co-Founder, Clinical Advisor
MS
Marjan Shamsaei
Senior Vice President Commercial and Portfolio Lead
DV
David V. Smith
Member of the Board of Directors